Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden fungus threat in ventilator pneumonia revealed

NCT ID NCT05671328

Knowledge-focused Sponsor: University Hospital, Lille Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at 263 adults on breathing machines who had signs of pneumonia. Researchers tested their blood and lung fluid to see how many had a serious fungal infection called invasive pulmonary aspergillosis. The goal was to find out how common this infection is in this group.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

263 people

The number who actually took part.

Started

Aug 2023

Finished

Jul 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients hospitalized in ICU

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient (age ≥ 18 years), * On invasive ventilation for more than 48 hours, * Suspected VAP, defined by the appearance or worsening of a radiological pulmonary infiltrate, associated with 2 of the following clinical criteria: * Fever ≥ 38° C or hypothermia ≤ 36.5° C * Leukocytes \> 12x109 or \< 4x109/L * Purulent tracheal secretions Exclusion Criteria: * Neutropenic patients (neutrophils \< 0.5G/L), * Previous diagnosis of IPA, * Minor patients.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Pulmonary aspergillosis invasive are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

invasive aspergillosis Invasive Pulmonary Aspergillosis nosocomial infection Pneumonia, Ventilator-Associated

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Pulmonary aspergillosis invasive Ventilator associated pneumonia

Contacts and locations

Locations

  • Pôle de Réanimation Hôpital R. Salengro, CHU de Lille

    Lille, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.